82819
document
A comparison of the systemic bioactivity of inhaled budesonide and fluticasone propionate in normal subjects . 1 . The aim of this study was to compare the systemic bioactivity of low and high doses of inhaled budesonide and fluticasone propionate given by respective dry powder inhaler devices . 2 . A randomised , single blind cross-over design was used in nine healthy subjects who were given 800 micrograms day-1 of budesonide Turbohaler ( B800 ) for 1 week , followed by 1 week of 1600 micrograms day-1 ( B1600 ) , or fluticasone Diskhaler 750 micrograms day-1 ( F750 ) for 1 week followed by 1 week of 1500 micrograms day-1 ( F1500 ) . There was a 1 week washout between treatments with fluticasone or budesonide . A twice daily dosing regime was used and mouth-rinsing was employed to reduce gut bioavailability as well as to obviate local adverse effects . 3 . Parameters of hypothalmic-pituitary adrenal ( HPA ) axis activity and bone metabolism were measured at baseline ( B0/F0 ) , at the end of each week of treatment and after the 1 week washout ( F0 or B0 ) . 4 . Both fluticasone and budesonide significantly ( P < 0.05 ) attenuated the post tetracosactrin serum cortisol at low and high doses whilst early morning cortisol was unchanged . No dose-response effect was observed with either drug , and there was no significant difference between treatment with fluticasone or budesonide . 5 . Neither budesonide nor fluticasone produced significant suppression of plasma osteocalcin , although the higher doses of both drugs significantly reduced fasting urinary calcium levels . ( ABSTRACT TRUNCATED AT 250 WORDS )
82820
Intervention_Pharmacological
budesonide
82821
Intervention_Pharmacological
fluticasone propionate
82822
Intervention_Pharmacological
inhaled budesonide
82823
Intervention_Pharmacological
fluticasone propionate
82824
Intervention_Pharmacological
800 micrograms day-1 of budesonide Turbohaler ( B800 )
82825
Intervention_Pharmacological
fluticasone Diskhaler 750 micrograms day-1
82826
Intervention_Pharmacological
fluticasone
82827
Intervention_Pharmacological
budesonide
82828
Intervention_Pharmacological
fluticasone
82829
Intervention_Pharmacological
budesonide
82830
Outcome_Physical
hypothalmic-pituitary adrenal ( HPA ) axis activity
82831
Outcome_Physical
bone metabolism
82832
Outcome_Physical
post tetracosactrin serum cortisol
82833
Outcome_Other
dose-response effect
82834
Outcome_Other
difference
82835
Participant_Condition
normal subjects .
82836
Participant_Condition
nine healthy subjects